Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 22, 2024 - Issue 1-3
Submit an article Journal homepage
630
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Immunocompromised patients and COVID-19: how do we protect those most at risk?

Jochen Schneidera Department of Internal Medicine II, Infectious Diseases, School of Medicine, University Hospital Klinikum rechts der Isar, Munich, GermanyCorrespondence[email protected]
View further author information
,
Johanna Erbera Department of Internal Medicine II, Infectious Diseases, School of Medicine, University Hospital Klinikum rechts der Isar, Munich, GermanyView further author information
,
Lutz Rendersb Department of Internal Medicine II, Nephrology, School of Medicine, University Hospital Klinikum rechts der Isar, Munich, GermanyView further author information
&
Christoph D. Spinnera Department of Internal Medicine II, Infectious Diseases, School of Medicine, University Hospital Klinikum rechts der Isar, Munich, GermanyView further author information
Pages 1-3 | Received 10 Sep 2023, Accepted 13 Dec 2023, Published online: 20 Dec 2023

References

  • Tenforde MW, Link-Gelles R. Reduction in COVID-19-related mortality over time but disparities across population subgroups. Lancet Public Health. 2023;8(5):e327–e328. doi: 10.1016/S2468-2667(23)00078-6
  • Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalized immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLOS Med. 2023;20(1):e1004086. doi: 10.1371/journal.pmed.1004086
  • Hall VG, Solera JT, Al-Alahmadi G, et al. Severity of COVID-19 among solid organ transplant recipients in Canada, 2020-2021: a prospective, multicenter cohort study. CMAJ. 2022;194:E1155–E1163. doi: 10.1503/cmaj.220620
  • Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021;78(12):1510–1514. doi: 10.1001/jamaneurol.2021.3599
  • Miura M, Fukumoto M, Komatsu N, et al. Temporary reduction of immunosuppression enhances production of anti-S antibody against severe acute respiratory syndrome coronavirus 2 after vaccination in kidney transplant recipients. Int J Urol. 2022;29(12):1505–1510. doi: 10.1111/iju.15027
  • Piccicacco N, Zeitler K, Ing A, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the omicron surge. J Antimicrob Chemother. 2022;77(10):2693–2700. doi: 10.1093/jac/dkac256
  • Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med. 2022;387(5):468–470. doi: 10.1056/NEJMc2207519
  • Solera JT, Árbol BG, Bahinskaya I, et al. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. Am J Transplant. 2023;23(1):78–83. doi: 10.1111/ajt.17199
  • Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342–e349. doi: 10.1093/cid/ciac443
  • Radcliffe C, Palacios CF, Azar MM, et al. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge. Am J Transplant. 2022;22(10):2458–2463. doi: 10.1111/ajt.17098
  • Driouich JS, Bernadin O, Touret F, et al. Activity of sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model. Antiviral Res. 2023;215:105638. doi: 10.1016/j.antiviral.2023.105638
  • Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin Infect Dis. 2023;76(8):1403–1411. doi: 10.1093/cid/ciac933
  • Calderón-Parra J, Múñez-Rubio E, Fernández-Cruz A, et al. Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2022;74(10):1786–1794. doi: 10.1093/cid/ciab700
  • Mikulska M, Sepulcri C, Dentone C, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77(2):280–286. doi: 10.1093/cid/ciad181
  • Rabascall CX, Lou BX, Navetta-Modrov B, et al. Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab. BMJ Case Rep. 2021;14(8):e243469. doi: 10.1136/bcr-2021-243469

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.